Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study

Colorectal Cancer Metastatic Clinical Trial

— REGAIN  

Official title:

A Phase II Study of Cetuximab Rechallenge in Combination With Irinotecan in Advanced Metastatic Colorectal Cancer Without KRAS or NRAS or BRAF Mutation (All Wild Type) for Patients Pretreated With FOLFIRI and Cetuximab in First Line With Stopping Cetuximab for Progressive Disease After a Previous Response (Partial Response or Complete Response) and After Treatment With a Fluoropyrimidine, Oxaliplatin Plus Bevacizumab Regimen

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02316496
• Other study ID #: REGAIN C13-2
• Status: Terminated
• Phase: Phase 2
• First received: December 8, 2014
• Last updated: July 29, 2017
• Start date: September 23, 2015
• Est. completion date: January 2017

Study information

• Verified date: January 2017
• Source: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main objective of this study is to evaluate the objective response rate at two months (complete disappearance of the disease and partial disappearance of the disease) obtained after administration of combination therapy with cetuximab and irinotecan in the patients with metastatic colorectal cancer.

Secondaries objectives will be assessed progression-free survival, overall survival, toxicity, quality of life.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 2
• Est. completion date: January 2017
• Est. primary completion date: January 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Signed and dated informed consent

• Histologically confirmed metastatic adenocarcinoma of the colon or rectum

• All Wild Type KRAS (exon 2 [codons 12-13], exon 3 [codons - 61]; exon 4 [codon 146]), NRAS (exon 2 [ codons 12-13] and exon 3 [codon 61) and BRAF (V600E) tumor ( local assessment performed either on primary tumor or metastasis)

• First line chemotherapy regimen with a fluoropyrimidine and Irinotecan (FOLFIRI) + cetuximab with initial partial or complete response and progressive disease (PD) with PD = 6 weeks after the last administration of cetuximab

• Other line(s) of therapy(ies) including the following drugs: second line oxaliplatin based chemotherapy with fluoropyrimidines (5FU or capecitabine) + bevacizumab and eventually regorafenib (possible but not mandatory) and progression or limiting toxicity to the last therapy with a minimum of 4 months between last injection of cetuximab and inclusion in this study

• At least one measurable lesion = 10 mm as assessed by CT-scan or MRI (Magnetic Resonance Imaging) according to RECIST v1.1 (All sites must be evaluated = 28 days prior to the enrolment)

• Age =18 years

• World Health Organization (WHO) Performance status (PS) 0-2

• The patient has adequate organ function, defined as :

Absolute neutrophil count (ANC) = 1.5 x 109/L, hemoglobin = 9 g/dL, and platelets = 100 x 109/L.Total bilirubin = 1.5 times upper limit of normal value (ULN), serum alkaline phosphatase level < 5 times ULN, Serum creatinine level <150µM/l

• For female patients of childbearing potential, negative pregnancy test within 7 days before starting the study drug

• Men and women are required to use adequate birth control during the study (when applicable) and until 6 months after the end of study treatment

• Registration in a national health care system (CMU included)

Exclusion Criteria:

• Previous chemotherapy other than adjuvant therapy with different combinations than those scheduled in first and second line treatment

• Presence of any KRAS, BRAF or NRAS mutation by allelic discrimination on tumor DNA

• Significant cardiovascular disease including unstable angina or myocardial infarction within 12 months before initiation of study treatment or a history of ventricular arrhythmia (treated or not)

• History or evidence of central nervous system metastasis (systematic CT-scan or MRI not mandatory if no clinical symptoms)

• Known allergy or hypersensitivity to cetuximab

• Previous or concurrent malignancy except for basal or squamous cell skin cancer, in situ carcinoma of the cervix, low-risk prostate cancer according to d'Amico classification or other solid tumors treated curatively and without evidence of recurrence for at least 5 years prior to the study

• Active or uncontrolled clinically serious infection

• Known human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)-related illness

• Other serious and uncontrolled non-malignant disease

• Pregnancy

• Breast feeding

• Treatment with any other investigational medicinal product within 28 days prior to study entry

• Known Gilbert's syndrome

• Concomitant administration of live, attenuated virus vaccine such as yellow fever vaccine

• Concomitant use with St John's Wort

• Chronic inflammatory bowel disease and/or Bowel obstruction

Related Conditions & MeSH terms

• Colorectal Cancer Metastatic
• Colorectal Neoplasms

Intervention

Drug:
• cetuximab
cetuximab 500mg/m²/ IV infusion, (q2w)
• Irinotecan
Irinotecan 180mg/m², in 500ml NaCl 0.9% solution, 90 min IV infusion (q2w)

Locations

Country	Name	City	State
France	Hôpital Beaujon	Clichy
France	Centre hospitalier Alpes Leman	Contamine sur Arve
France	Centre Georges François Leclerc	Dijon
France	CHD Vendée	La Roche/ Yon
France	Hôpital Privé Jean Mermoz	Lyon
France	Hôpital Européeen	Marseille
France	Institut Paoli-Calmettes	Marseille
France	CHU Caremeau	Nîmes
France	CHU Cochin	Paris
France	Hôpital Pitié Salpêtrière	Paris
France	Hôpital Saint Antoine	Paris
France	Hôpital Saint Louis	Paris
France	Hôpital Tenon	Paris
France	Clinique Armoricaine de Radiologie	Saint Brieuc
France	Groupe hospitalier Public du Sud de l'Oise -site de Senlis	Senlis
France	Centre de radiothérapie - Clinique Sainte Anne	Strasbourg
France	Hôpital Foch	Suresnes
France	Hôpitaux du Léman	Thonon les Bains
France	CHU Tours - Hôpital Trousseau	Tours
France	Clinique Générale	Valence

Sponsors (1)

Lead Sponsor	Collaborator
Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective response rate (ORR)		At 2 months
Secondary	Objective response rate (ORR)	Best response observed during investigational treatment combination. From the start of treatment until treatment failure	up to 27 months
Secondary	Disease control rate (DCR)	The proportion of patients with tumor response (Complete response or partial response) or tumor stabilization as best response during study treamtent	up to 27 months
Secondary	Progression-free survival (PFS)	Time from the date of inclusion to the date of the first progressive disease (RECIST criteria) or death (any cause)	up to 27 months
Secondary	Duration of response (DOR)	Only for patients with tumor response (complete reposne or partial response) , from first confirmed response to first observed progression (PD) or death due to PD during study treatment	up to 27 months
Secondary	Time to response (TTR)	Time from the date of inclusion to the date of the first confirmed CR or PR during study treatment	up to 27 months
Secondary	Time to progression (TTP)	Time from the date of inclusion to the date of the first obseved progression (PD), or death due to progression during the study treatment	up to 27 months
Secondary	Time to treatment failure (TTF)	Time from the date of inclusion to the date the decision was made to end the study treatment for any reason	up to 27 months
Secondary	Duration of stable disease (DoSD)	Only for patient with a stable disease (SD) as best response during the study treatment, from date of inclusion to the first observed progression (PD) or death due to progression	up to 27 months
Secondary	Overall survival (OS)	From the date of inclusion to the date of patient death, due to any cause, or to the last date the patient was known to be alive	up to 27 months
Secondary	Adverse Events (CTCAE v.4.03)		Up to 27 months
Secondary	Quality of life	Using EORTC Quality of Life Questionnaire - C30 (QLQ-C30) and the Dermatology Life Quality Index (DLQI ) questionnaires	Up to 27 months
Secondary	Respose rate	RAS and BRAF status in circulating tumoral DNA	up to 27 months
Secondary	PFS	RAS and BRAF status in circulating tumoral DNA	up to 27 months